| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
Valutazione dell’ansia come variabile interveniente nel processo decisionale, in donne positive alle varianti patogenetiche BRCA 1 e/o 2 |
NA |
in corso |
Tumore alla mammella |
SSD Psiconcologia Clinica - |
|
(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA |
II |
in corso |
MELANOMA OCULARE |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
|
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN‑c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER |
II |
in corso |
tumore ovarico, delle tube di falloppio e peritoneo |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
III |
in corso |
Melanoma avanzato |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
|
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) |
II/III |
in corso |
Melanoma uveale metastatico |
- SC Oncologia Clinica Sperimentale del Melanoma – Immunoterapia e Terapie Innovative |
